Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer


      To prospectively determine whether multiparametric magnetic resonance imaging (mpMRI)–based staging is a more accurate independent predictor of outcome than traditional clinical variables for patients undergoing brachytherapy and external beam radiation therapy.

      Methods and Materials

      The primary endpoints were biochemical (nadir plus 2 ng/mL) and metastatic failure. Descriptive, univariate, and multivariate competing risks analyses were performed. The cumulative incidence rates were estimated to describe the cumulative risk of the events of interest. The magnitude of the increased risk was estimated using univariate and multivariate subdistribution hazard ratios.


      A total of 185 patients had undergone prospective treatment (123 with high risk and 62 with intermediate risk). The median age was 71 years (range 56-82). Of the patients, 20.5% had mpMRI-determined (mrT) stage mrT1-mrT2b, 37.3% had mrT2c, 31% had mrT3a, and 11.2% had mrT3b. The Gleason score was 6 in 22.2%, 7 in 49.5%, and 8 to 10 in 28.2%. The median baseline prostate-specific antigen was 11.7 ng/mL (range 2.9-153). After a median follow-up period of 46 months (range 16-70), 15 patients (8.1%) had developed biochemical failure and 9 (4.9%) had developed distant metastases. None of the traditional clinical variables (prostate-specific antigen, Gleason score, clinical stage) predicted for biochemical or metastatic failure. The multivariate competing risk analysis demonstrated that the 2 independent predictors of biochemical failure were the presence of extraprostatic extension (EPE; mrT3a; hazard ratio [HR] 4.80; P = .035) and presence of seminal vesicle invasion (SVI; mrT3b; HR 10.17; P = .003) on mpMRI. The only independent predictor of metastatic failure was the percentage of positive cores on prostate biopsy (HR 13.95; P = .014). After excluding patients with SVI, the only independent predictor of biochemical failure and metastatic failure was the presence of EPE (stage mrT3a) on mpMRI (HR 4.36; P = .042; and HR 5.76; P = .010, respectively).


      The pretreatment mpMRI findings might be more accurate independent predictors of the outcome than traditional clinical variables. In particular, the presence of EPE, SVI and a greater percentage of positive cores on biopsy predicted for a worse prognosis.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • King C.R.
        • McNeal J.E.
        • Gill H.
        • et al.
        Extended prostate biopsy scheme improves reliability of Gleason grading: Implications for radiotherapy patients.
        Int J Radiat Oncol Biol Phys. 2004; 59: 386-391
        • Pinthus J.H.
        • Witkos M.
        • Fleshner N.E.
        • et al.
        Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: Implication on outcome.
        J Urol. 2006; 176: 979-984
        • Hoffman R.M.
        Screening for prostate cancer.
        N Engl J Med. 2011; 365: 2013-2019
        • Chamie K.
        • Sonn G.A.
        • Finley D.S.
        • et al.
        The role of magnetic resonance imaging in delineating clinically significant prostate cancer.
        Urology. 2014; 83: 369-375
        • Hegde J.V.
        • Chen M.H.
        • Mulkern R.V.
        • et al.
        Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2013; 85: e101-e107
        • Kamrava M.
        • Kishan A.U.
        • Margolis D.J.
        • et al.
        Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
        Pract Radiat Oncol. 2015; 5: 411-416
        • Song S.H.
        • Pak S.
        • Park S.
        • et al.
        Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: Role of multiparametric magnetic resonance imaging.
        J Urol. 2014; 192: 402-408
        • Gomez-Iturriaga A.
        • Casquero F.
        • Urresola A.
        • et al.
        Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy.
        Prospective phase II trial. Radiother Oncol. 2016; 119: 91-96
        • Gomez-Iturriaga A.
        • Casquero F.
        • Pijoan J.I.
        • et al.
        Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
        Radiother Oncol. 2018; 126: 278-282
        • Cornud F.
        • Rouanne M.
        • Beuvon F.
        • et al.
        Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5 Tesla: Should we reconsider the indirect signs of extracapsular extension according to the D'Amico tumor risk criteria?.
        Eur J Radiol. 2012; 81: e591-e597
        • Roach M.
        • Hanks G.
        • Thames H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • National Comprehensive Care Network
        Clinical practice guidelines in oncology.
        (Available at:)
        • Couñago F.
        • Del Cerro E.
        • Díaz-Gavela A.A.
        • et al.
        Tumor staging using 3.0 T multiparametric MRI in prostate cancer: Impact on treatment decisions for radical radiotherapy.
        SpringerPlus. 2015; 4: 789
        • Hegde J.V.
        • Demanes D.J.
        • Veruttipong D.
        • et al.
        Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
        Brachytherapy. 2017; 16: 1106-1112
        • de Rooij M.
        • Hamoen E.H.J.
        • Witjes J.A.
        • et al.
        Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta-analysis.
        Eur Urol. 2016; 70: 233-245
        • Stephenson A.J.
        • Kattan M.W.
        • Eastham J.A.
        • et al.
        Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
        J Clin Oncol. 2009; 27: 4300-4305
        • Pierorazio P.M.
        • Ross A.E.
        • Schaeffer E.M.
        • et al.
        A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.
        J Urol. 2011; 185: 1691-1697
        • Padhani A.R.
        • Petralia G.
        • Sanguedolce F.
        Finding minimal extraprostatic disease: Who cares?.
        Eur Urol. 2016; 70: 246-247
        • Karavitakis M.
        • Ahmed H.U.
        • Abel P.D.
        • et al.
        Margin status after laparoscopic radical prostatectomy and the index lesion: Implications for preoperative evaluation of tumor focality in prostate cancer.
        J Endourol. 2012; 26: 503-508
        • Delongchamps N.B.
        • Beuvon F.
        • Eiss D.
        • et al.
        Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer.
        Prostate Cancer Prostatic Dis. 2011; 14: 232-237
        • Okamura T.
        • Umemoto Y.
        • Yamashita K.
        • et al.
        Pitfalls with MRI evaluation of prostate cancer detection: Comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens.
        Urol Int. 2006; 77: 301-306
        • Abdollah F.
        • Suardi N.
        • Gallina A.
        • et al.
        Extended pelvic lymph node dissection in prostate cancer: A 20-year audit in a single center.
        Ann Oncol. 2013; 24: 1459-1466
        • Park S.Y.
        • Oh Y.T.
        • Jung D.C.
        • et al.
        Prediction of micrometastasis (< 1 cm) to pelvic lymph nodes in prostate cancer: Role of preoperative MRI.
        AJR Am J Roentgenol. 2015; 205: W328-W334
        • Febles C.
        • Valicenti R.K.
        Combining external beam radiotherapy with prostate brachytherapy: Issues and rationale.
        Urology. 2004; 64: 855-861
        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        • et al.
        Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
        • Rodda S.
        • Tyldesley S.
        • Morris W.J.
        • et al.
        ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol. 2017; 98: 286-295
        • Fonteyne V.
        • Villeirs G.
        • Speleers B.
        • et al.
        Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
        Int J Radiat Oncol Biol Phys. 2008; 72: 799-807
        • Crook J.
        • Ots A.
        • Gaztañaga M.
        • et al.
        Ultrasound-planned high-dose-rate prostate brachytherapy: Dose painting to the dominant intraprostatic lesion.
        Brachytherapy. 2014; 13: 433-441


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.